Q-omics provides the consensus-scored ZBTB21 profile across patient tissues and cancer cell-line models. ZBTB21 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB21 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ZBTB21 RNA expression shows 20,801 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where ZBTB21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB21 survival associations across molecular data types. ZBTB21 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB21 RNA expression–survival associations across cancer types. High ZBTB21 expression shows unfavorable associations in THCA, LGG and MESO, but favorable associations in KIRC, LUAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB21 RNA expression.
This table summarizes ZBTB21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB21 shows lower tumor expression in THCA, KIRC, KIRP, LUSC, KICH and LUAD. The THCA box plot shows higher ZBTB21 RNA expression in normal versus tumor tissue (log2 FC = −1.447, t-test p < 0.001).
This table shows molecular features associated with ZBTB21 in patient tissues and cancer cell lines. In patient samples, ZBTB21 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
